↓ Skip to main content

Dove Medical Press

Article Metrics

Role of aripiprazole in treatment-resistant schizophrenia

Overview of attention for article published in Neuropsychiatric Disease and Treatment, May 2012
Altmetric Badge

About this Attention Score

  • Above-average Attention Score compared to outputs of the same age (53rd percentile)
  • Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter
2 tweeters

Citations

dimensions_citation
11 Dimensions

Readers on

mendeley
65 Mendeley
Title
Role of aripiprazole in treatment-resistant schizophrenia
Published in
Neuropsychiatric Disease and Treatment, May 2012
DOI 10.2147/ndt.s13830
Pubmed ID
Authors

Nilufar Mossaheb

Abstract

About one third of patients with schizophrenia respond unsatisfactorily to antipsychotic treatment and are termed "treatment-resistant". Clozapine is still the gold standard in these cases. However, 40%-70% of patients do not improve sufficiently on clozapine either. In the search for more efficacious strategies for treatment-resistant schizophrenia, drugs with different pharmacological profiles seem to raise new hopes, but are they valid? The aim of this review was to evaluate the evidence for aripiprazole as a potential strategy in monotherapy or combination therapy for patients with treatment-resistant schizophrenia. The evidence for aripiprazole monotherapy and for the combination of aripiprazole with psychotropics other than clozapine is scant, and no recommendation can be made on the basis of the currently available data. More effort has been made in describing combinations of aripiprazole and clozapine. Most of the open-label and case studies as well as case reports have shown positive effects of this combination on overall psychopathology and to some extent on negative symptoms. Several reports describe the possibility of dose reduction for clozapine in combination with aripiprazole, a strategy that might help so-called "treatment-intolerant" patients. The findings of four randomized controlled trials with respect to changes in psychopathology seem less conclusive. The most commonly found beneficial effects are better metabolic outcomes and indicators of the possibility of reducing the clozapine dose. However, other side effects, such as akathisia, are repeatedly reported. Further, none of the studies report longer-term outcomes. In the absence of alternatives, polypharmacy is a common strategy in clinical practice. Combining aripiprazole with clozapine in clozapine-resistant or clozapine-intolerant patients seems to be worthy of further investigation from the pharmacological and clinical points of view.

Twitter Demographics

The data shown below were collected from the profiles of 2 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 65 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Chile 1 2%
Canada 1 2%
Unknown 63 97%

Demographic breakdown

Readers by professional status Count As %
Student > Bachelor 15 23%
Researcher 11 17%
Student > Master 8 12%
Other 7 11%
Student > Doctoral Student 6 9%
Other 14 22%
Unknown 4 6%
Readers by discipline Count As %
Medicine and Dentistry 34 52%
Psychology 7 11%
Agricultural and Biological Sciences 5 8%
Nursing and Health Professions 4 6%
Biochemistry, Genetics and Molecular Biology 2 3%
Other 7 11%
Unknown 6 9%

Attention Score in Context

This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 29 May 2012.
All research outputs
#2,274,769
of 4,507,509 outputs
Outputs from Neuropsychiatric Disease and Treatment
#577
of 908 outputs
Outputs of similar age
#34,484
of 75,176 outputs
Outputs of similar age from Neuropsychiatric Disease and Treatment
#16
of 30 outputs
Altmetric has tracked 4,507,509 research outputs across all sources so far. This one is in the 48th percentile – i.e., 48% of other outputs scored the same or lower than it.
So far Altmetric has tracked 908 research outputs from this source. They receive a mean Attention Score of 3.3. This one is in the 36th percentile – i.e., 36% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 75,176 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 53% of its contemporaries.
We're also able to compare this research output to 30 others from the same source and published within six weeks on either side of this one. This one is in the 43rd percentile – i.e., 43% of its contemporaries scored the same or lower than it.